Electromyography in Patients on Chronic Pyridostigmine Therapy
Electromyography in Patients on Chronic Pyridostigmine Therapy
We intend to measure evoked EMG at two sites in subjects who are chronically taking
 pyridostigmine.
The investigators are intending to enroll Patients who are chronically treated with
 pyridostigmine for the treatment of any medical condition and presenting at the
 investigators' outpatient clinics for follow up appointment. Subjects taking pyridostigmine
 for the treatment of myasthenia gravis will be excluded. Both adults and children older than
 12 years of age will be approached. Those subjects that agree to participate will be asked to
 sign an informed consent. For the participation of minors a parental (or guardian) consent
 and subject assent will be obtained. Those that participate will answer a few questions
 pertaining to their medical history and will then undergo electromyograph (CMAP) measurement
 with repetitive stimulation at 2 sites (ulnar nerve at the wrist and the accessory nerve in
 the neck). Evoked electromyogram will be recorded on a computer hard drive. Eight percent or
 greater decrement in the CMAP response on repetitive stimulation will be considered positive.
Inclusion Criteria:

 -  Subjects who have been taking pyridostigmine for the treatment of any condition other
 than myasthenia gravis

 Exclusion Criteria

 -  Subjects taking pyridostigmine for the treatment of myasthenia gravis will be
 excluded.